- Home
- NKTR vs PDX Comparison
NKTR vs PDX Comparison
Compare NKTR & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | PDX |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | NY |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.8M | 931.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | PDX |
|---|---|---|
| Price | $36.10 | $19.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $111.83 | N/A |
| AVG Volume (30 Days) | ★ 688.3K | N/A |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $13.52 |
| 52 Week High | $66.92 | $21.05 |
Technical Indicators
Market Signals| Indicator | NKTR | PDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 45.73 |
| Support Level | $35.03 | $19.22 |
| Resistance Level | $38.29 | $20.20 |
| Average True Range (ATR) | 2.30 | 0.38 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 18.73 | 71.57 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.